{"analyses":[{"ciLowerLimit":"0.730","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.976","estimateComment":"The estimation was performed on stratified data.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0219","paramType":"Hazard Ratio (HR)","paramValue":"0.844","statisticalComment":"The analysis was performed on stratified data.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.4","upperLimit":"14.5","value":"13.3"},{"groupId":"OG001","lowerLimit":"10.8","upperLimit":"12.7","value":"11.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"536"},{"groupId":"OG001","value":"536"}],"units":"Participants"}],"description":"OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 14-day cycle, participants received ramucirumab followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nRamucirumab: 8 mg/kg administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG000","title":"Ramucirumab + FOLFIRI"},{"description":"On Day 1 of each 14-day cycle, participants received placebo followed by other study treatment in the following sequence: Irinotecan, Folinic Acid and 5-Fluorouracil. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\nPlacebo: Administered intravenously.\n\nIrinotecan: 180 mg/m\\^2 administered intravenously.\n\nFolinic Acid: 400 mg/m\\^2 administered intravenously.\n\n5-Fluorouracil: 400 mg/m\\^2 bolus immediately followed by 2400 mg/m\\^2 continuous infusion.","id":"OG001","title":"Placebo + FOLFIRI"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Participants censored: Ramucirumab + FOLFIRI group = 164; Placebo + FOLFIRI= 139.","reportingStatus":"POSTED","timeFrame":"Randomization to Date of Death from Any Cause Up to 39.36 Months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}